							<u> </u>						Sheet _	1 (A) of 13		
SUBSTITUTE (MODIFIED)	Weight	1449					F COMMERCE MARK OFFICE	ATTY. DOCKET NO. SERIAL NO. RENAS/03				_ NO.				
Hm.)											APPLICANT Michael B. Foster					
(37 CFR 72)		ENE	Sse se	evera	i shee	ets i	f necessary)			FILING April 20						
	& TRAU						U.:	S. PATEN	T DOCUMENTS							
EXAMINER INITIAL		Р	ATEN	T NU	MBEF		ISSUE DATE		PATENTEE		CLASS	SUBCLASS		FILING DATE IF APPROPRIATE		
	A.A					L							!			
	A.B															
	A.C															
	A.D				_								RE	CEIVED		
	A.E	-	-	4	-	L					- 		00	0 3 2002		
	A.F	\sqcup	4	4		<u> </u>							00			
-	A.G	\sqcup	_			<u> </u>				<u> </u>		71	-CH C	ENTER 1600/290		
	A.H	\sqcup	4			_						11	_0110			
	A.I					<u> </u>					<u> </u>					
	A.J					L										
	A.K	Щ.									<u></u>					
				F	OREIG	N F	ATENTS OR	PUBLISHE	D FOREIGN PA	TENT APP	PLICATIONS					
		DOCUMENT NUMBER					PUBLICATIO DATE	N	COUNTRY OR PATENT OFFICE		CLASS	SUBC	SUBCLASS (YES/NO			
	A.L															
	A.M															
	A.N															
	A.O					\int										
	A.P															
	A.Q															
				ОТ	HER (000	CUMENTS (Inc	luding Au	thor, Title, Date	, Place of	f Publication)					
CMK	A.R	Murray et al., <u>Pre-treatment IGF-1 level is the major determinant of GH dosage in adult GH deficiency</u> , Clinical Endocrinology, Vol. 52, No. 5, 2000, 537-542.														
CMR	A.S	Drake et al., Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults, Journal of Clinical Endocrinology & Metabolism, Vol. 83, No. 11, 1998, 3913-3919.														
CMK	A.T	Johannsson et al., <u>Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults,</u> Clinical Endocrinology, Vol. 47, No. 5, 1997, 571-581.														
EXAMINER	C	L, I	_		/-	_			DATE CONSI	DERED	10/9	102		`		
EXAMINER: II	nitial if c	itatio	n cons	sidere	ed, w	neth	er or not in co	onformano	e. Draw line th	rough cit	ation only if	not in co	onforma	nce and not		

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE (MODELED)	ŢΟ-	144	9				U.S. DEPA PATENT A	RTME	NT OF COMMERCE RADEMARK OFFICE	ATTY. DOCKET NO. RENAS/03			Sheet 2 (B) of 13 SERIAL NO.			
/ -	0 1 2002		IN ST	FOR TATI	RMAT EMEN	ION IT B	DISC Y AF	CLOSURE			APPLICANT Michael B. Foster					
(37 CHE)		\	(Use	e sev	veral	shee	ets if	necessary		FILING April 2	DATE 0, 2001	GR	GROUP			
	& TRACE							l	J.S. PA	TENT DOCUMENTS						
EXAMINER INITIAL			PATI	ENT	NUV	ивег	₹	ISSUE DATE		PATENTEE	CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
	B.A															
	В.В															
	B.C													_		
	B.D												DE	<u>:</u>	EIVED	
	B.E															
	B.F												0.0	TC	3 2002	
	B.G													- K	TED 1800/2900	
	в.н												TECH	CEM	TER 1600/2900	
	B.I															
	B.J															
	B.K															
					FC	REI	GN P	ATENTS O	R PUB	LISHED FOREIGN PA	TENT AP	PLICATIONS				
	DOCUMENT NUMBER							PUBLICAT DATE		COUNTRY (· · · · · · · · · · · · · · · · · · ·		SUBCLASS		TRANSLATION (YES/NO)	
	B.L															
	в.м							-								
	B.N															
	В.О															
	В.Р															
	B.Q															
					ОТ	HER	DOC	UMENTS (Includi	ng Author, Title, Dat	e, Place	of Publication)			
CMK	B.R	C:	arroll ourna	l et al of	al., <u>G</u> Clini	irow cal l	th H	ormone De crinology a	ficienc nd Me	y in Adulthood and the tabolism, Vol. 83, No.	ne Effect o. 2, 199	s of Growth H 8, 382-395.	lormone Re	place	ment: A Review,	
	B.S		,													
	1	+														

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.